Brief: Spero Therapeutics Q2 EPS USD -0.33
05/08/2024 21:01
Aug 05 (Reuters) - Spero Therapeutics Q2 income from operation USD -19.061 million. * Q2 net income USD -17.862 million * Q2 operating expenses USD 29.258 million
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)